Journal
MOLECULAR THERAPY-ONCOLYTICS
Volume 3, Issue -, Pages -Publisher
CELL PRESS
DOI: 10.1038/mto.2016.11
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
- NICHD NIH HHS [K12 HD028820] Funding Source: Medline
Ask authors/readers for more resources
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, on target/off tumor recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available